Johns Hopkins

Questions discussed in this category

How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?

1 Answer available

Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?

1 Answer available

How would you treat a patient with metastatic RCC who developed posterior reversible encephalopathy syndrome (PRES) on a TKI-containing regimen?

Would you consider re-challenging with a different TKI?

1 Answer available

Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?

1 Answer available

For metastatic prostate cancer, when would you add carboplatin to docetaxel or cabazitaxel?

1 Answer available

How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

1 Answer available

For metastatic clear cell RCC, would you consider cabozantinib + nivolumab after progression on first line ipilimumab + nivolumab?

Or what is your preferred regimen for stage IV ccRCC following progression on IO/IO?

4 Answers available

How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

2 Answers available

How would you proceed for a patient with metastatic gastric-type adenocarcinoma, with vaginal and inguinofemoral disease only, who experiences complete response to her vaginal tumor but residual inguinal disease?

History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...

2 Answers available

How do you treat patients with newly diagnosed metastatic MiT Family Translocation Renal Cell Carcinoma?

MiT subfamily translocations = TFE3, TFEB, TFC, or MiTF

2 Answers available

After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?

Does post docetaxel PSA influence your decision?

1 Answer available

How would you manage a patient with recurrent granulosa tumor following secondary, R0 cytoreduction, and negative inhibins postoperatively?

Primary, R0 debulking in 2019, stage IA. Low volume recurrence, now again optimally cytoreduced.

1 Answer available

Are there any clinical scenarios where you would recommend adjuvant docetaxel for localized prostate cancer?

1 Answer available

How would you manage a clinically inoperable, stage IIIB, MMR deficient uterine cancer?

Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement. ER/PR and HER2 testing are pending.

1 Answer available

How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Ann. Oncol.,

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

JAMA Oncol,

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.

Urology, 2001-08

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

Gynecologic oncology, 2014-11

Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.

Practical radiation oncology, 2019

Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.

Cancer, 2010-11-15

Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.

Ann Oncol, 2010 Feb 12

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

N Engl J Med, 2021 Mar 4

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J. Clin. Oncol., 2019 Jul 22

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Clinical genitourinary cancer, 2018-06

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Cancer treatment and research communications, 2019

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Urology, 2013-06

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Prostate Cancer Prostatic Dis, 2020 Feb 28

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Cancer, 2019 Dec 1

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Invest New Drugs, 2017 Oct 25

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.

Prostate cancer and prostatic diseases, 2018-04

Platinum sensitivity in metastatic prostate cancer: does histology matter?

JCO Precis Oncol, 2020

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.

Lancet Oncol, 2019 Sep 09

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Prostate, 2022 Jun 08

The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.

N Engl J Med, 2022 Feb 17

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Related Topics